Deferoxamine (Standard)
Based on 3 publication(s) in Google Scholar
Deferoxamine (Standard) is the analytical standard of Deferoxamine. This product is intended for research and analytical applications. Deferoxamine (Deferoxamine B) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine upregulates HIF-1α levels with good antioxidant activity. Deferoxamine also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19.
For research use only. We do not sell to patients.
- Purity: 96.37%
- CAS No.: 70-51-9
- Formula: C25H48N6O8
- Molecular Weight:560.68
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Product Information
-
Chemical Information
- Purity & Documentation
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Deferoxamine (Standard)
More
Product Information
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 70-51-9
-
Appearance Solid
-
Molecular Weight 560.68
-
Formula C25H48N6O8
-
Color White to off-white
-
SMILES
O=C(N(CCCCCN)O)CCC(NCCCCCN(C(CCC(NCCCCCN(C(C)=O)O)=O)=O)O)=O
-
Synonyms
Deferoxamine B (Standard); Deferriferrioxamine B (Standard); Deferrioxamine (Standard)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Cell Rep
SLC6A8-mediated creatine uptake suppresses ERK2-FSP1 signaling and induces ferroptosis in colorectal cancer. [Abstract]2025 Sep 1;44(9):116139. PMID: 40892544 -
J Med Virol
HPV16 Enhances Radiosensitivity in Esophageal Squamous Cell Carcinoma by Promoting De Novo Fatty Acid Synthesis and Disulfidptosis. [Abstract]2025 Nov;97(11):e70699. PMID: 41231234 -
Front Biosci (Landmark Ed)
Immune Characteristics of eQTL and Gene Risk Model and the Inhibitory Effect of DCTD and RRAS on Ferroptosis in Glioblastoma. [Abstract]2025 Aug 30;30(8):42844. PMID: 40917066
Purity & Documentation
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Duscher D, et al. Comparison of the Hydroxylase Inhibitor Dimethyloxalylglycine and the Iron Chelator Deferoxamine in Diabetic and Aged Wound Healing. Plast Reconstr Surg. 2017 Mar;139(3):695e-706e. [Content Brief]
[2]. Dongiovanni P, et al. Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. Am J Pathol. 2008 Mar;172(3):738-47. [Content Brief]
[3]. Wang G, et al. In vitro assessment of deferoxamine on mesenchymal stromal cells from tumor and bone marrow. Environ Toxicol Pharmacol. 2017 Jan;49:58-64. [Content Brief]
[4]. Wu Y, et al. Neuroprotection of deferoxamine on rotenone-induced injury via accumulation of HIF-1 alpha and induction of autophagy in SH-SY5Y cells. Neurochem Int. 2010 Oct;57(3):198-205. [Content Brief]
[5]. Bellotti D, et al. Deferoxamine B: A Natural, Excellent and Versatile Metal Chelator. Molecules. 2021 May 28;26(11):3255. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Deferoxamine (Standard) Related Classifications
Cat. No.: HY-B1625R
Powered by Bioz
- Deferoxamine (Standard)
- 70-51-9
- Deferoxamine B (Standard)
- Deferriferrioxamine B (Standard)
- Deferrioxamine (Standard)
- Reference Standards
- HIF/HIF Prolyl-Hydroxylase
- Reactive Oxygen Species (ROS)
- Apoptosis
- Akt
- Autophagy
- diabetes mellitus
- neovascularization
- cancer
- Alzheimer’s disease
- MEFs
- TAMSCs
- BMMSCs
- COVID-19
- PD
- SH-SY5Y
- Inhibitor
- inhibitor
- inhibit